RESEARCH

Open Access

Construction of a nomogram for preoperative deep vein thrombosis in pelvic fracture patients

Wencai Li^{1†}, He Ling^{1†}, Zhao Huang¹, Yonghui Lao¹, Junjie Liu¹, Gaoyong Deng¹, Wei Su¹ and Rongbin Lu^{1*}

Abstract

Background In recent years, the incidence of pelvic fractures has been on the rise, predominantly affecting the elderly population. Deep vein thrombosis may lead to poor prognosis in patients. monocyte-to-lymphocyte ratio is novel biomarkers of inflammation, and this study aims to verify their predictive effect and construct the nomogram model.

Method This study used binary logistic regression analysis to predict the predictive effect of MLR on the occurrence of DVT in pelvic fractures patients. And use R studio to construct nomogram model.

Result The results showed that Age (1.04 [1.01, 1.07], p = 0.006), WBC (1.44 [1.28, 1.61], p < 0.001), and MLR (2.11 [1.08, 4.13], p = 0.029) were independent predictive factors. The nomogram demonstrated good predictive performance with small errors in both the training and validation groups, and most clinical patients could benefit from them.

Conclusion The nomogram constructed based on MLR can assist clinicians in early assessment of the probability of DVT occurrence.

Keywords Pelvic fractures, Deep vein thrombosis, Monocyte to lymphocyte ratio, Nomogram

Background

In recent years, the incidence of pelvic fractures has been on the rise, predominantly affecting the elderly population. These fractures are mainly caused by trauma and account for approximately 1.5-3% of all skeletal injuries, with an increase of about 2.4 times in the past 30 years. The one-year mortality rate associated with these fractures ranges from 14 to 25% [1]. The severity of fractures

[†]Wencai Li and He Ling contributed equally to this work.

*Correspondence:

Rongbin Lu

gxmulrb@163.com

¹Dept. orthopedics trauma and hand surgery, the First Affiliated Hospital of Guangxi Medical University, NO. 6 ShuangYong Road, Nanning 530022, Guangxi, China

varies from avulsion of the bone epiphysis to complete rupture of the pelvic ring. Previous studies have shown that up to 30% of pelvic fractures are not initially detected on X-rays [2]. In unstable fractures treated conservatively, the prognosis is usually poor, often requiring adequate reduction and surgical stabilization to avoid long-term complications [3, 4]. Pelvic fractures are often accompanied by various complications, including pelvic bleeding, urethral injury, infection, multiple systemic injuries, deep vein thrombosis, and death [5–8]. Pelvic fractures have become a significant public health issue and a socioeconomic burden [9].

Deep vein thrombosis (DVT) is common in trauma patients [10], and studies have shown that the incidence of DVT is higher in pelvic fractures compared to other types of fractures [11]. A study in Taiwan found that the



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/.

overall incidence of DVT and symptomatic pulmonary embolism in patients with pelvic and acetabular fractures was 3.48%, with 46.1% of patients being asymptomatic [5]. Many scholars have pointed out that early screening for DVT should be conducted in patients with pelvic fractures to achieve early prevention [12]. Therefore, we need more intuitive, simpler, and easily obtainable predictive indicators in the early stages of the disease to meet the goals of early prevention and treatment in clinical practice.

In recent years, the predictive role of inflammatory factors in the occurrence of DVT in fracture patients has received much attention [13]. Melinte Răzvan Marian et al. [14] found that preoperative systemic immuneinflammatory factors and other inflammatory factors can effectively predict the formation of deep vein thrombosis in patients after total knee arthroplasty. Zhang Liang et al. [15] constructed a nomogram based on systemic immune-inflammatory factors to predict the occurrence of preoperative DVT in elderly patients with hip fractures. Gao Zhida et al. [16] suggested that the neutrophil-to-lymphocyte ratio can predict the occurrence of preoperative DVT in patients with ankle fractures. Melinte RM et al. [17] believe that preoperative MLR strongly predicts the occurrence of acute DVT in patients after total knee arthroplasty. However, there have been no studies on the development of a nomogram for the occurrence of deep vein thrombosis in patients with pelvic fractures using the monocyte-to-lymphocyte ratio (MLR) as a novel inflammatory factor.

Therefore, the aim of this study is to collect the results of routine blood tests and biochemical examinations upon patient admission, and to develop a nomogram for the prediction of preoperative deep vein thrombosis in patients with pelvic fractures based on the MLR. This nomogram aims to provide a non-invasive, early, and simple prediction tool to assist clinicians in making early decisions.

Materials and methods Patient section

This is a retrospective study. A total of patients diagnosed with pelvic fractures from January 2015 to January 2023 at the First Affiliated Hospital of Guangxi Medical University hospital were included in this study. The inclusion criteria were as follows: patients diagnosed with pelvic fractures based on the following criteria: (a) Clear history of trauma; (b) Clinical manifestations including widespread pain, exacerbation of pain in the lower limbs or when sitting, local tenderness, congestion, rotation of the lower limbs, and deformity; (c) Imaging examinations (X-ray and CT) indicating pelvic fractures; (d) Non critical patients; (e) Age>18 years. The exclusion criteria were as follows: (1) Inability to obtain hematological examination and vascular color Doppler ultrasound results; (2) Recent use of anticoagulants or antiplatelet drugs; (3) Concomitant immune system and hematological disorders; (4) Patients with critical illness and shortterm death; (5) Patients with infectious diseases and acute or chronic infections.

According to the US Critical Care Guidelines [18], all patients included will be treated with low-molecularweight heparin as early as possible (within 24 h) after injury to prevent thrombosis, combined with mechanical prophylaxis. This regimen will be used as a routine for all patients.

As this is a retrospective study, the ethics committee approved the study without requiring patients to sign informed consent forms, in accordance with national laws and institutional agreements. In this study, patients' personal identifying information will be anonymized.

Data collection and definition

This study collected baseline clinical data and laboratory test results including complete blood count, blood biochemistry, and coagulation function. The baseline clinical data included gender, age, affected side, history of hypertension, history of diabetes, history of heart disease, history of hepatitis, history of alcohol consumption, and smoking history.

Additionally, the study collected the following laboratory data upon patient admission White blood cell count (WBC), Red blood cell count (RBC), Hemoglobin (HGB), Mean corpuscular hemoglobin concentration (MCHC), Mean corpuscular volume (MCV), Neutrophils (NC), Lymphocyte (LYM), Monocyte (MONO), Eosinophils (Eos), Basophil (Baso), Albumin (ALB), Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Total bilirubin (TBIL), Creatinine (Cr), Blood urea nitrogen (BUN), Prothrombin time (PT), Activated partial thromboplastin time (APTT), Fibrinogen (FIB), and other relevant data. Among these, the inflammatory factor validated in this study is monocyte-to-lymphocyte ratio (MLR)=monocyte /lymphocyte.

All of our patients have completed the collection of blood routine tests and related testing items in the emergency department or at the time of admission.

Outcome

All patients were diagnosed through lower limb venous color Doppler ultrasound examination. Color Doppler ultrasound examination has high sensitivity and accuracy, and is widely used in clinical practice, making it the preferred method for DVT diagnosis [19]. In this study, the occurrence of DVT before surgery in patients with pelvic fractures was considered as the outcome event, The presence of DVT was defined as a positive result, while the absence of DVT was defined as a negative result. All patients were diagnosed with deep vein thrombosis for the first time.

Statistical methods

In this study, the data was first randomly divided into a training group and a validation group in a 7:3 ratio using SPSS 21.0 (SPSS Inc., Chicago, IL). Then, a comparison of baseline data between the training group and the validation group was conducted to verify their comparability.

Next, the training group data was divided into groups based on the presence or absence of DVT, and comparisons were made between the clinical data and laboratory test results. For continuous data, the Shapiro-Wilk test was used to determine normality. If the data followed a normal distribution, it was presented as mean±standard deviation, and one-way analysis of variance (ANOVA) was used for group comparisons. If the data did not follow a normal distribution, it was presented as median (25th percentile, 75th percentile), and the Kruskal-Wallis test was used for group comparisons.

Categorical data were described using frequencies (percentages), and group comparisons were performed using the chi-square test or Fisher's exact test. A *p*-value less than 0.05 was considered statistically significant for two-sided tests.

To calculate the optimal cutoff value, sensitivity, specificity, and other results for factors with statistically significant differences in the inter-group comparison of the training group using SPSS 21.0 software. Additionally, use GraphPad Prism 9.5.0 to plot the receiver operating characteristic (ROC) curve for the differentiating factors.



Fig. 1 Flow chart of this study

Table 1 Baseline data table for comparison of training test and
validation test

| Variable | training test | validation test | Sum | р |
|---------------|---------------|-------------------|--------------|-------|
| | (n=269) | (<i>n</i> = 115) | (N=384) | |
| Sex | | | | 0.590 |
| Male | 144 (53.53%) | 65 (56.52%) | 209 (54.43%) | |
| Female | 125 (46.47%) | 50 (43.48%) | 175 (45.57%) | |
| Age(years) | 46 (34,57) | 48 (31.5,61) | 47 (33,58) | 0.526 |
| Hypertension | | | | 0.906 |
| No | 242 (89.96%) | 103 (89.57%) | 345 (89.84%) | |
| Yes | 27 (10.04%) | 12 (10.43%) | 39 (10.16%) | |
| Diabetes | | | | 0.066 |
| No | 254 (94.42%) | 114 (99.13%) | 368 (95.83%) | |
| Yes | 15 (5.58%) | 1 (0.87%) | 16 (4.17%) | |
| Heart disease | | | | 1.000 |
| No | 265 (98.51%) | 114 (99.13%) | 379 (98.7%) | |
| Yes | 4 (1.49%) | 1 (0.87%) | 5 (1.3%) | |
| Smoke | | | | 0.393 |
| No | 203 (75.46%) | 82 (71.3%) | 285 (74.22%) | |
| Yes | 66 (24.54%) | 33 (28.7%) | 99 (25.78%) | |
| Alcoholism | | | | 0.326 |
| No | 209 (77.7%) | 84 (73.04%) | 293 (76.3%) | |
| Yes | 60 (22.3%) | 31 (26.96%) | 91 (23.7%) | |
| Hepatitis | | | | 0.379 |
| No | 261 (97.03%) | 114 (99.13%) | 375 (97.66%) | |
| Yes | 8 (2.97%) | 1 (0.87%) | 9 (2.34%) | |

We use the optimal cutoff value as the threshold to classify the clinical factors. We included all variables in the univariate binary logistic regression analysis, and then included single factors with P<0.05 in the multivariate binary logistic regression analysis to obtain independent predictors(P<0.05). All variables we included are binary variables.

Based on the results of the multivariable binary logistic regression, use R Studio (version 4.2.2) to draw a nomogram for the independent predictive factors in the training group. Evaluate the predictive performance of the model using the ROC curve and the area under the curve (AUC). Calculate the average error of the model using a calibration plot. Analyze the clinical benefits of the model using a decision curve analysis (DCA) plot. Additionally, perform relevant analyses and plot graphs for the validation group to validate the effectiveness of the model.

Result

A total of 578 patients with pelvic fractures were collected for this study. Among them, 194 patients were excluded due to the aforementioned factors, and a total of 384 patients were included in the retrospective study, as shown in Fig. 1. The training group consisted of 269 patients, and the validation group consisted of 115 patients.

Baseline data for the two groups were compared. There are 125 and 50 females (46.47%, 43.48%) in the training

and validation groups, respectively, with median ages of 46 years (34,57) and 48 years (31.5,61). The number of patients with hypertension, diabetes, heart disease, smoking, drinking and hepatitis history was 27 and 12 (10.04%, 10.43%), 15 and 1 (5.58%, 0.87%), 4 and 1 (1.49%, 0.87%), 66 and 33 (24.54%, 28.7%), 60 and 31 (22.3%, 28.3%), 8 and 1 (2.97%, 0.87%), respectively. There were no statistically significant differences in baseline data between the two groups (p>0.05), indicating comparability of the data (Table 1).

The training group data was divided into two groups based on the presence or absence of DVT. The group with DVT was defined as the DVT group, and the group without DVT was defined as the No DVT group. A comparison was made between the two groups, and the results showed that RBC, HGB, MCV, WBC, NC, MLR, LYM, MONO, and albumin had statistically significant differences among the different groups of DVT (p < 0.05) (Table 2). Box plots were created for the factors with significant differences to facilitate visual comparison (Fig. 2). The optimal cutoff values, sensitivity, and specificity were calculated for each differentiating factor (Table 3). ROC curves were plotted, and the area under the curve (AUC) was calculated (Fig. 3). The results showed that the optimal cutoff value for RBC was 3.505*1012/L, with a sensitivity of 0.621 and specificity of 0.652. For HGB, the optimal cutoff value was 105.8 g/L, with a sensitivity of 0.672 and specificity of 0.571. The optimal cutoff value for MCV was 88.675fL, with a sensitivity of 0.638 and specificity of 0.586. The optimal cutoff value for WBC was 10.625*109/L, with a sensitivity of 0.793 and specificity of 0.753. The optimal cutoff value for NC was 8.515*109/L, with a sensitivity of 0.793 and specificity of 0.758. The optimal cutoff value for MLR was 0.506, with a sensitivity of 0.759 and specificity of 0.591.

Including various clinical factors in a univariate binary logistic regression analysis, the results showed that Age (1.79 [1.01, 3.19], p=0.047), RBC (0.33 [0.18, 0.6], p<0.001), HGB (0.37 [0.2, 0.68], p=0.001), MCV (2.49 [1.36, 4.57], p=0.003), WBC (11.66 [5.72, 23.77], p<0.001), NC (11.98 [5.87, 24.45], p<0.001), MLR (4.54 [2.34, 8.83], p<0.001), LYM (0.31 [0.17, 0.57], p<0.001), MONO (3.26 [1.78, 5.96], p<0.001), ALB (0.41 [0.21, 0.8], p=0.009), AST (2.38 [1.08, 5.21], p=0.031), and Cr (0.5 [0.26, 0.95], p=0.035) were all risk factors for DVT (Table 4).

When significant factors from the univariate analysis were included in a multivariate binary logistic regression analysis, the results showed that Age (1.04 [1.01, 1.07], p=0.006), WBC (1.44 [1.28, 1.61], p<0.001), and MLR (2.11 [1.08, 4.13], p=0.029) were independent predictive factors (Table 5).

In order to further validate the predictive ability of various factors for patients with pelvic fractures,

| Image: constraint of the second se | Variable | No DVT (<i>n</i> = 208) | DVT | Sum | p |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|--------------------------|-----------------------|---------------------|---------|
| bet 115 (55.29%) 29 (47.54%) 14 (53.53%) 125 Fernalic 93 (44.71%) 32 (52.4%) 125 (46.47%) 0.093 Age 45 (34.55) 51 (34.61) 125 (46.47%) 0.093 Age 45 (34.55) 51 (34.61) 22 (85.96%) 125 (46.47%) No 188 (03.38%) 54 (88.52%) 22 (85.96%) 100 Diabotes No 197 (94.71%) 57 (93.44%) 25 (98.51%) . . No 10 (32.98%) 60 (98.36%) 26 (98.51%) . . No 15 (73.08%) 10 (16.39%) 263 (92.75.6%) . . No 15 (73.08%) 10 (16.39%) 60 (22.3%) . . No 15 (73.08%) 10 (16.39%) 60 (22.3%) . . No 15 (76.44%) 00 (96.35%) 08 (19.77%) . . No 15 (97.64.4%) 09 (97.79%) < | | | (1-61) | (10-209) | 0.296 |
| Mate 115 (32.29%) 29 (47.9%) 144 (53.9%) Fernale 93 (47.1%) 32 (52.46%) 125 (66.7%) Age 45 (34.55) 51 (34.61) 46 (34.57) 0.033 Hypertension 242 (89.96%) 242 (89.96%) 0.671 No 188 (90.38%) 54 (88.52%) 242 (89.96%) 0.671 No 188 (90.38%) 54 (88.52%) 247 (0.04%) 0.95 No 115 (5.29%) 24 (56.0%) 15 (5.5%) 1 No 115 (5.29%) 254 (94.42%) 1 1 No 115 (2.29%) 4 (6.50%) 256 (93.5%) 1 Netart (alsass 11 (6.4%) 205 (98.5%) 1 0.95 No 15 (7.3.0%) 11 (8.3%) 20 (7.7%) 1 Viss 9 (2.5.6%) 10 (16.3%) 20 (97.7%) 1 Viss 9 (2.5.6%) 10 (16.3%) 20 (97.7%) 1 Viss 19 (7.6.4%) 20 (97.5%) 1 3.62 (2.6.4%) 0.02 No <t< td=""><td>Sex</td><td>115 (55 200/)</td><td>20 (47 5 40/)</td><td>144 (52 520)</td><td>0.280</td></t<> | Sex | 115 (55 200/) | 20 (47 5 40/) | 144 (52 520) | 0.280 |
| ftmlab 53 (22.48%) 12 (24.8%) 12 (26.9%) 10 (0.93 Hyperension 0.671 0.093 No 18 (90.38%) 54 (88.5%) 24 (89.96%) No 197 (94.71%) 57 (93.4%) 27 (10.04%) Diabets 0.95 0.95 No 197 (94.71%) 57 (93.4%) 15 (5.8%) Heart disease 1 1 1 No 20 (96.5%) 60 (98.36%) 265 (98.5%) Yes 3 (1.44%) 1 (1.64%) 4 (1.49%) Snoke 152 (73.0%) 10 (16.3%) 203 (75.4%) Yes 56 (26.92%) 10 (16.3%) 209 (77.5%) Yes 49 (23.56%) 11 (18.0%) 209 (77.5%) Yes 92 (166.53%) 16 (4.64%) 61 (27.0%) No 159 (76.44%) 96 (28.64.04) 37.3 (3.04.46.0) 0.002 Hegattis 73.3 (3.04,47.31) | Male | 115 (55.29%) | 29 (47.54%) | 144 (53.53%) | |
| Age 45 (34,3) 5 (34,61) 40 (34,57) 0.003 No 188 (90,38%) 5 (488,25%) 242 (89,56%) 1 No 188 (90,38%) 5 (488,25%) 242 (89,56%) | Female | 93 (44.71%) | 32 (52.40%) | 125 (40.47%) | 0.000 |
| Implementation Impleme | Age | 45 (34,55) | 51 (34,61) | 46 (34,57) | 0.093 |
| No 188 (93.98%) 54 (88.52%) 22 (10.04%) Pies 10 (96.21%) 7 (11.48%) 22 / (10.04%) Diabetes 17 (94.71%) 57 (93.44%) 25 (94.92%) No 197 (94.71%) 57 (93.44%) 15 (55.98%) Heart disease 1 1 No 205 (98.51%) 4 (65.66%) 265 (98.51%) Yes 3 (1.44%) 1 (1.64%) 4 (1.49%) 1 Smoke 1 1 (1.64%) 6 (24.54%) 1 No 15 (73.08%) 51 (83.61%) 203 (75.46%) 1 Yes 56 (26.92%) 10 (16.39%) 66 (24.54%) 3 No 159 (76.44%) 50 (81.97%) 209 (77.7%) 1 Yes 49 (23.56%) 11 (18.03%) 60 (22.39%) 1 No 201 (96.63%) 60 (98.36%) 209 (77.7%) 1 Yes 201 (96.63%) 60 (98.36%) 20.977.7%) 1 Kettis 3.63 (28.64.04) 3 (29.44.46) 0.002 No | Hypertension | 100 (00 200() | 54 (00 500/) | 242 (00 000) | 0.671 |
| Yes 20 (9,6%) / (1.4%%) 20 (9,6%) (1.4%%) (1.4%%) (1.4%%) No 197 (94,71%) 57 (93,44%) 254 (94,42%) (1.4%%) Yes 11 (5.29%) 60 (98,36%) 60 (98,36%) 255 (98,51%) (1.4%%) Heart disease 1 205 (98,56%) 60 (98,36%) 265 (98,51%) (1.4%%) Smoke 1 (1.6%%) 203 (75,46%) (1.4%%) Smoke 56 (26,92%) 10 (16,39%) 66 (24,54%) (1.4%%) Yes 56 (26,92%) 10 (16,39%) 60 (92,36%) 60 (92,36%) 209 (77,7%) Yes 49 (23,56%) 50 (81,97%) 209 (77,7%) (1.4%%) 11 (18,03%) 209 (77,7%) Yes 49 (23,56%) 10 (16,49%) 60 (92,36%) 201 (97,03%) 11 (18,03%) 209 (77,7%) 168 (1.4%%) 37 (3.44,46) 0.002 Yes 7 (3.37%) 11 (1.64%) 82 (27%) 0.001 10.56 (22,33) 0.01 MC(f10/1) 836 (32,24,56) 36 (26,64,04) 37 (3.04,46,0) 0.00 | NO | 188 (90.38%) | 54 (88.52%) | 242 (89.96%) | |
| Dabbets (0) No 197 (94.71%) 57 (93.44%) 254 (94.42%) Yes 11 (5.29%) 4 (656%) 15 (5.58%) Heart disease 1 5 568%) 10 Yes 3 (1.44%) 11 (1.64%) 4 (1.49%) 1 Snoke 50 (25.92%) 10 (16.39%) 60 (24.54%) 1 No 152 (7.3.08%) 51 (83.61%) 60 (22.56%) 3 No 152 (7.3.08%) 50 (81.97%) 60 (22.5%) 3 No 150 (76.46%) 50 (81.97%) 60 (22.3%) 1 No 197 (64.49%) 50 (81.97%) 60 (22.3%) 1 No 150 (66.39%) 60 (83.6%) 60 (22.5%) 1 No 197 (64.49%) 11 (18.03%) 60 (22.5%) 1 No 197 (64.49%) 10 (18.03%) 60 (23.9%) 1 Kertol ⁷ /1 49 (23.5%) 10 (18.03%) 60 (23.9%) 1 Kertol ⁷ /1 38 (3.274.6%) 11 (18.03%) 16 (24.5%) 0. | Yes | 20 (9.62%) | 7 (11.48%) | 27 (10.04%) | |
| No 197 (94, 71%) 57 (93.44%) 254 (94.42%) Yes 11 (5.29%) 4 (656%) 15 (5.58%) Heart disease 1 5.58%) 6.66%) 265 (98.51%) Yes 31.44%) 1 (1.64%) 265 (98.51%) 0.003 Snoke 0.033 5.05% 0.037 0.037 No 152 (73.08%) 10 (16.39%) 620 (27.54%) 0.032 Yes 620.29%) 10 (16.39%) 60 (22.3%) 0.062 Yes 159 (76.44%) 50 (81.97%) 209 (77.7%) 7.83 Alcoholism 11 (18.03%) 60 (92.36%) 0.02 7.88 No 201 (96.63%) 60 (98.36%) 86 (12.23%) 0.02 Yes 73.37%) 11 (14.4%) 80.297%) 0.02 K0C(10 ¹ /L) 386 (32.24.56) 336 (28.64.04) 37.3 (3.44.46) 0.002 MCG(10 ¹ /L) 10.817.42.504 9.81 (32.24.833.515) 32.895 (32.17.83.36) 0.657 MCH(10 ¹ /L) 39.62 (3.1.32.36.28) 32.81 (32.24.83.35.15) 32.85 | Diabetes | | | | 0.95 |
| Yes 11 (5,25%) 15 (5,5%) Heart disease I 1 No 205 (98,56%) 60 (98,36%) 265 (98,51%) I Yes 3 (1,44%) 1 (1,64%) 4 (1,49%) 0.093 Smoke . 0.093 205 (78,56%) 0.013 0.023 (75,46%) 0.013 Yes 56 (26,92%) 10 (16,39%) 66 (24,54%) 0.033 Alcoholism . 0.362 . 0.362 No 159 (76,44%) 50 (81,97%) 60 (22,35%) . 0.362 No 49 (23,56%) 11 (18,03%) 60 (22,35%) . 0.738 No 201 (96,63%) 60 (98,36%) 82,97%) . 0.373 (3,04,446) 0.002 HEghtitis . 9,138 (63,22,456) 3,36 (28,64,04) 3,73 (3,04,46) 0.002 No 10,187,23,33,28% 3,281 (52,24,335,15) 3,289 (521,78,336) 0.657 WCY(IQ) 3,266 (52,71,058) 148 (10,72,178 32,56 (52,71,033) 0.002 MCCY(0 ¹ / ₁ | No | 197 (94.71%) | 57 (93.44%) | 254 (94.42%) | |
| Heart Disease 1 No 205 (98.56%) 60 (98.36%) 265 (98.51%) Yes 3 (1.44%) 1 (1.64%) 4 (1.49%) Smoke 0.093 0.03 (75.46%) 0.093 No 152 (73.08%) 51 (83.61%) 66 (24.54%) 0.093 Alcoholism 0.01 (16.39%) 60 (22.3%) 0.01 (16.39%) 0.02 (27.9%) No 159 (76.44%) 50 (81.97%) 0.00 (22.3%) 1 Yes 0.19 (76.44%) 60 (98.36%) 60 (22.3%) 1 No 159 (76.44%) 60 (98.36%) 60 (22.3%) 1 Yes 201 (96.63%) 60 (98.36%) 80 (22.3%) 1 Yes 21 (96.63%) 60 (98.36%) 81 (23.93) 0.01 MCV(10 ¹ /L) 3.86 (32.24.65) 3.56 (28.67.04) 3.20 (44.64) 0.002 H68(g/L) 108.17 ± 25.04 98.41 ± 25.09 105.59 (52.17.83.36) 0.67 MCV(10 ¹ /L) 8.52 (66.71.058) 14.8 (10.72.17.8) 9.15 (7.11.12.11) 0.002 MCHC10 ⁰ /L) | Yes | 11 (5.29%) | 4 (6.56%) | 15 (5.58%) | |
| No 205 (98.5%) 60 (98.36%) 205 (98.5%) 205 (98.5%) Yes 3 (1.44%) 1 (1.64%) 4 (1.49%) 0093 Smoke 203 (75.46%) 203 (75.46%) 0093 Yes 52 (73.08%) 51 (83.61%) 203 (75.46%) 0056 Yes 59 (76.44%) 101 (01.63%) 209 (77.7%) 0362 No 159 (76.44%) 50 (81.97%) 60 (22.3%) 01057 Yes 49 (23.56%) 11 (18.03%) 60 (22.3%) 0105 No 201 (96.63%) 60 (98.36%) 82.07%) 0105 Yes 7 (3.37%) 11 (16.4%) 82.97%) 0102 HGB(g/L) 108.17 ± 25.04 9.41 ± 25.09 105.96 ± 25.33 0012 MCV(fL) 87.12 (83.07.91.04 9.18 (42.45.57) 32.895 (32.17.83.36) 0.657 WBC(*10 ⁷ /L) 8.55 (67.10.58 14.8 (10.22.17.8) 9.15 (7.11.21.1) 0.001 NCY(fL) 8.712 (83.07.91.04 9.16 (63.15.137) 7.35 (4.68.10.3) 0.001 LYM(*10 ⁷ /L) 1.85 (| Heart disease | | | | 1 |
| Yes 3 (1.44%) 1 (1.64%) 4 (1.49%) Smoke . .003 No 152 (73.08%) 51 (83.61%) 203 (75.46%) Yes 56 (26.92%) 10 (16.39%) 66 (24.54%) Alcoholism . . . No 159 (76.44%) 50 (81.97%) 209 (77.7%) Yes 49 (23.56%) 11 (18.03%) 60 (22.3%) . Hepatitis No 201 (96.63%) 60 (98.36%) 261 (97.03%) . Yes 7 (33.7%) 1 (16.4%) 82.97%) . . RBC(*10 ¹² /L) 83.63 (22.4.56) 3.62 (28.4.04) 3.73 (3.04.4.46) 0.002 MCK(0/L) 81.7 ± 25.04 98.41 ± 25.09 105.96 ± 25.33 0.01 MCV(L) 87.1 (83.07.91.04) 91.8 (84.65.92.23) 87.75 (83.46.91.31) 0.02 MCH(0/L) 32.6 (22.1.82.362.62) 32.8 (22.1.82.362.62) 6.001 1.5 (7.1.1.2.11) 0.001 MCH(0/L) 32.6 (26.0.67) | No | 205 (98.56%) | 60 (98.36%) | 265 (98.51%) | |
| Smoke 0.093 No 152 (73.08%) 51 (88.61%) 203 (75.46%) 10 No 56 (26.52%) 10 (16.39%) 66 (24.54%) | Yes | 3 (1.44%) | 1 (1.64%) | 4 (1.49%) | |
| No 15 (23,08%) 51 (83,61%) 203 (75,46%) Yes 56 (26,92%) 10 (16.39%) 66 (45,4%) Alcoholism 159 (76,44%) 50 (81,97%) 209 (77,7%) Yes 49 (23,56%) 11 (18,03%) 60 (22,3%) Hepatris 50 (81,97%) 60 (98,36%) 60 (92,36%) No 201 (96,63%) 60 (98,36%) 81,297%) Yes 7(3,37%) 11 (16,4%) 82,297%) RBC(*10 ¹² /L) 3.86 (3,22,4,56) 3.36 (2,86,4.04) 3.73 (3,04,4.46) 0.002 MCK(fg)/L 10,17 ± 25,04 9841 ± 25,09 105 ob 5 ± 25,33 0.01 MCV(fg)/L 8.71 (2,83,79,10.4) 90,18 (86,59,2.23) 87,75 (83,46,9,131) 0.62 MCH(fg/L) 8.29 (6,21,32,336.28) 12,81 (32,24,835.15) 32,89 (5,21,78,336.0) 0.65 MCH(fg/L) 8.55 (6,67,10.58) 14,81 (0.72,17.81 9,15 (7,11,2.11) <0.001 | Smoke | | | | 0.093 |
| Yes 56 (26.92%) 10 (16.39%) 66 (24.54%) Alcoholism | No | 152 (73.08%) | 51 (83.61%) | 203 (75.46%) | |
| Alcoholism 0.362 No 15976.44%) 50 (81.97%) 209 (77.7%) Yes 49 (23.56%) 11 (18.03%) 60 (22.3%) Hepatiti 201 (96.63%) 60 (98.36%) 261 (97.03%) Yes 7(3.37%) 116.44%) 8 (2.97%) RBC(*10 ¹² /L) 36 (32.24.56) 3.36 (28.64.04) 37.3 (3.04.44.61) 0.002 HGB(g/L) 108.17 ± 25.04 9.018 (84.65.92.23) 8.75 (8.34.69.13.1) 0.02 MCV(fL) 32.6 (32.13.23.36.28) 32.81 (32.24.83.35.15) 32.89 (32.17.8,33.6) 0.657 WBC(*10 ⁹ /L) 32.6 (32.13.23.36.28) 32.81 (32.24.8,33.51.57) 32.89 (32.17.8,33.6) 0.657 WC(*10 ⁹ /L) 32.6 (32.13.23.36.28) 32.81 (32.24.8,35.57) 32.89 (32.17.8,33.6) 0.650 MC(*10 ⁹ /L) 1.81 (3.0.9.12 1.26 (8.88,15.37) 7.35 (4.68,10.3) 0.60 MLR 0.45 (0.2.6.0.67) 0.66 (0.51,11.61) 0.49 (0.2.80.79) 0.60 MDNO (*10 ⁹ /L) 1.27 (0.88,192 0.95 (0.81,14) 1.22 (0.81,182) 0.02 MLMC 0.52 (0 | Yes | 56 (26.92%) | 10 (16.39%) | 66 (24.54%) | |
| No 159 (76.44%) 50 (81.97%) 209 (77.7%) Yes 49 (23.56%) 11 (18.03%) 60 (22.3%) Hepatitis 0.788 No 201 (96.63%) 60 (98.36%) 261 (97.03%) Yes 7(3.37%) 11.64%) 8 (2.97%) RBC(*10 ¹² /L) 3.86 (3.22.4.56) 3.36 (2.86.4.04) 3.73 (3.04.4.46) 0.002 HGB(g/L) 108.17 ± 25.04 98.41 ± 25.09 105.96 ± 25.33 0.01 MCV(ft) 3.29 (321.32.336.28) 328.1 (322.48,35.15) 328.95 (231.78,336) 0.657 MCH(10 ⁰ /L) 3.56 (6.67,10.58) 1.48 (10.72.17.8) 9.15 (7.11.2.11) 0.001 NC*(10 ⁰ /L) 6.18 (42.4.8.5) 1.64 (8.88,15.37) 7.35 (4.68,0.3) <0.001 | Alcoholism | | | | 0.362 |
| Yes49 (23.56%)11 (18.03%)60 (22.3%)Hepattis 0.788 No0106.63%)60 (98.36%)261 (97.03%)Yes7 (3.37%)11.164%)82.97%)RBC(*10 ¹² /L)386 (3.22.4.56)3.36 (2.86.4.04)3.73 (3.04.4.46)0.002HG8(g/L)108.17 ± 2.5.049.8.11 ± 2.5.09105.96 ± 2.5.330.1MCV(fL)87.12 (83.07.91.0.4)9.18 (84.65.92.2.3)87.57 (83.46.91.31)0.02MCH(g/L)8.55 (6.67.10.58)14.8 (10.72.17.8)32.895 (32.17.8.336.0)6.57WBC(*10 ⁹ /L)6.18 (4.2.4.8.5)12.64 (8.88,15.37)7.55 (4.6.8.10.3)<0.001 | No | 159 (76.44%) | 50 (81.97%) | 209 (77.7%) | |
| Hepatitis0.788No201(96.63%)60(98.36%)261(97.03%)Yes7(3.37%)1(6.4%)8(2.97%)RBC(*10 ¹² /L)38.6 (3.22.4.56)3.62.68.6.404)3.73 (3.04.4.6)0.002HGB(yL)108.17±2.50498.41±2.509105.96±2.5330.01MCV(fL)87.12 (83.07,91.04)91.8 (8.65,92.23)8.75 (8.3.66,91.31)0.02MCHC(g/L)8.75 (6.67,10.58)14.8 (10.72,17.8)91.57 (11.12,11)<0.01 | Yes | 49 (23.56%) | 11 (18.03%) | 60 (22.3%) | |
| No 201 (96.63%) 60 (98.36%) 261 (97.03%) Yes 7 (3.37%) 1 (1.64%) 8 (2.97%) RBC(*10 ⁻¹² /L) 3.86 (3.22,4.56) 3.36 (2.86,4.04) 3.73 (3.04,4.46) 0.002 HGB(p/L) 108.17 ± 25.04 98.41 ± 25.09 105.05 ± 25.33 0.11 MCV(fL) 329.6 (32.13,2.336.28) 328.1 (32.24,8.35.15) 82.95 (32.1.78,3.36) 0.657 MCH (10 ⁶ /L) 2.95 (63.71.0.58) 1.84 (10.27,17.8) 9.15 (7.1.1,2.1.1) <0.01 | Hepatitis | | | | 0.788 |
| Yes 7 (3.37%) 1 (1.64%) 8 (2.97%) RBC(*10 ¹² /L) 3.86 (3.22,4.56) 3.36 (2.86,4.04) 3.73 (3.04,4.46) 0.002 HGB(g/L) 108.17 ± 2.504 98.41 ± 25.09 105.96 ± 2.5.33 0.11 MCV(f) 87.12 (83.07.91.04) 90.18 (84.65.92.23) 87.75 (83.46,91.31) 0.02 MCH(g/L) 32.96 (321.32,336.28) 32.81 (322.48,35.15) 32.89 (521.78,336) 0.657 MBC(*10 ⁹ /L) 8.55 (66.71.0.58) 1.48 (10.72,17.8) 9.15 (7.11,21.11) <0.001 | No | 201 (96.63%) | 60 (98.36%) | 261 (97.03%) | |
| RBC(*10 ¹² /L) 386 (3.22,4.56) 3.36 (2.86,4.04) 3.73 (3.04,4.46) 0.002 HGB(g/L) 108.17±25.04 98.41±25.09 105.96±25.33 0.01 MCV(fL) 87.12 (83.07.91.04) 90.18 (84.65,92.23) 87.75 (83.46,91.31) 0.02 MCHC(g/L) 3296 (321.32,336.28) 328.1 (322.48,335.15) 328.95 (321.78,336) 0.657 WBC(*10 ⁹ /L) 8.55 (6.67,10.58) 14.8 (10.72,17.8) 91.5 (7.11,12.11) <0.001 | Yes | 7 (3.37%) | 1 (1.64%) | 8 (2.97%) | |
| HGB(g/L) 108.17±25.04 98.41±25.09 105.96±25.33 0.01 MCV(fL) 87.12 (83.07,91.04) 90.18 (84.65,92.23) 87.75 (83.46,91.31) 0.02 MCHC(g/L) 329.6 (321.32,336.28) 328.1 (322.48,335.15) 328.95 (321.78,336) 0.657 WBC(*10 ⁹ /L) 855 (667,10.58) 14.8 (10.72,17.8) 9.15 (7.11,12.11) <0.001 | RBC(*10 ¹² /L) | 3.86 (3.22,4.56) | 3.36 (2.86,4.04) | 3.73 (3.04,4.46) | 0.002 |
| MCV(fL) 87.12 (83.07,91.04) 90.18 (84.65,92.23) 87.75 (83.46,91.31) 0.02 MCHC(g/L) 329.6 (321.32,336.28) 328.1 (322.48,335.15) 328.95 (321.78,336) 0.657 WBC(*10 ⁹ /L) 8.55 (6.67,10.58) 14.8 (10.72,17.8) 9.15 (7.11,12.11) <0.001 | HGB(g/L) | 108.17±25.04 | 98.41 ± 25.09 | 105.96±25.33 | 0.01 |
| MCHC(g/L) 329.6 (321.32,336.28) 328.1 (322.48,335.15) 328.95 (321.78,336) 0.657 WBC(*10 ⁹ /L) 8.55 (667,10.58) 14.8 (10.72,17.8) 9.15 (7.11,2.11) <0.001 | MCV(fL) | 87.12 (83.07,91.04) | 90.18 (84.65,92.23) | 87.75 (83.46,91.31) | 0.02 |
| WBC(*10 ⁹ /L) 855 (667,1058) 148 (10.72,17.8) 9.15 (7.11,12.11) <0001 NC(*10 ⁹ /L) 6.18 (4.24,8.5) 12.64 (8.88,15.37) 7.35 (4.68,10.3) <0001 | MCHC(g/L) | 329.6 (321.32,336.28) | 328.1 (322.48,335.15) | 328.95 (321.78,336) | 0.657 |
| NC(*10°/L)6.18 (4.24,8.5)12.64 (8.88,15.37)7.35 (4.68,10.3)<001MLR0.45 (0.26,0.67)0.66 (0.51,1.16)0.49 (0.28,0.79)<001 | WBC(*10 ⁹ /L) | 8.55 (6.67,10.58) | 14.8 (10.72,17.8) | 9.15 (7.11,12.11) | < 0.001 |
| MLR0.45 (0.26,0.67)0.66 (0.51,1.16)0.49 (0.28,0.79)<0.001LYM(*10 ⁹ /L)1.27 (0.88,1.92)0.96 (0.68,1.46)1.22 (0.81,1.82)0.002MONO(*10 ⁹ /L)0.54 (0.41,0.73)0.72 (0.48,1.23)0.57 (0.42,0.78)<0.001 | NC(*10 ⁹ /L) | 6.18 (4.24,8.5) | 12.64 (8.88,15.37) | 7.35 (4.68,10.3) | < 0.001 |
| LYM(*10 ⁹ /L)1.27 (0.88, 1.92)0.96 (0.68, 1.46)1.22 (0.81, 1.82)0.002MONO(*10 ⁹ /L)0.54 (0.41, 0.73)0.72 (0.48, 1.23)0.57 (0.42, 0.78)<0.001 | MLR | 0.45 (0.26,0.67) | 0.66 (0.51,1.16) | 0.49 (0.28,0.79) | < 0.001 |
| MONO(*10 ⁹ /L)0.54 (0.41,0.73)0.72 (0.48,1.23)0.57 (0.42,0.78)<0.01Eos(*10 ⁹ /L)0.1 (0.01,0.18)0.08 (0.01,0.18)0.08 (0.01,0.18)0.6Baso(*10 ⁹ /L)0.02 (0.01,0.04)0.02 (0.01,0.03)0.02 (0.01,0.04)0.489PT(s)11.8 (10.9,12.7)11.85 (11.15,13)11.8 (10.9,12.78)0.446APTT(s)30 (27.8,32.88)30.05 (28.12,33.42)30 (27.9,33.32)0.502FIB(g/L)4.04 (3.1,5.01)4.44 (3.2,5.34)4.06 (3.11,5.04)0.254ALB(g/L)36.62 ± 6.1834.42 ± 5.736.15 ± 6.140.026GGT(U/L)25.5 (17,47)23 (15,38)24 (17,43)0.408ALT(U/L)29 (15,48)28 (21,49)29 (15.5,48.5)0.735AST(U/L)29.5 (19,57)36 (25,54)31 (19.5,57)0.175TBL(umol/L)12.3 (7.8,18.2)14.7 (9.5,21.7)12.55 (8.5,18.38)0.138Cr(umol/L)59 (47,72.25)53 (43.5,66)58 (46,71.5)0.209 | LYM(*10 ⁹ /L) | 1.27 (0.88,1.92) | 0.96 (0.68,1.46) | 1.22 (0.81,1.82) | 0.002 |
| Eos(*10°/L)0.1 (0.01,0.18)0.08 (0.01,0.18)0.08 (0.01,0.18)0.6Baso(*10°/L)0.02 (0.01,0.04)0.02 (0.01,0.03)0.02 (0.01,0.04)0.489PT(s)11.8 (10.9,12.7)11.85 (11.15,13)11.8 (10.9,12.78)0.446APTT(s)30 (27.8,32.88)30.05 (28.12,33.42)30 (27.9,33.32)0.502FIB(g/L)4.04 (3.1,5.01)4.44 (3.2,5.34)4.06 (3.11,5.04)0.254ALB(g/L)36.62 ± 6.1834.42 ± 5.736.15 ± 6.140.026GGT(U/L)25.5 (17,47)23 (15,38)24 (17,43)0.408ALT(U/L)29 (15,48)28 (21,49)29 (15.5,48.5)0.735AST(U/L)29.5 (19,57)36 (25,54)31 (19.5,57)0.175TBL(umol/L)12.3 (7.8,18.2)14.7 (9.5,21.7)12.55 (8.5,18.38)0.138Cr(umol/L)59 (47,72.25)53 (43.5,66)58 (46,71.5)0.209PLIN(mmon(L))4.0 (28.6,20)4.8 (25.5,21)4.80 (27.75,41)0.474 | MONO(*10 ⁹ /L) | 0.54 (0.41,0.73) | 0.72 (0.48,1.23) | 0.57 (0.42,0.78) | < 0.001 |
| Baso(*10°/L)0.02 (0.01,0.04)0.02 (0.01,0.03)0.02 (0.01,0.04)0.489PT(s)11.8 (10.9,12.7)11.85 (11.15,13)11.8 (10.9,12.78)0.446APTT(s)30 (27.8,32.88)30.05 (28.12,33.42)30 (27.9,33.32)0.502FIB(g/L)4.04 (3.1,5.01)4.44 (3.2,5.34)4.06 (3.11,5.04)0.254ALB(g/L)36.62 ± 6.1834.42 ± 5.736.15 ± 6.140.026GGT(U/L)25.5 (17,47)23 (15,38)24 (17,43)0.408ALT(U/L)29 (15,48)28 (21,49)29 (15.5,48.5)0.735AST(U/L)29.5 (19,57)36 (25,54)31 (19.5,57)0.175TBL(umol/L)12.3 (7.8,18.2)14.7 (9.5,21.7)12.55 (85,18.38)0.138Cr(umol/L)59 (47,72.25)53 (43.5,66)58 (46,71.5)0.209 | Eos(*10 ⁹ /L) | 0.1 (0.01,0.18) | 0.08 (0.01,0.18) | 0.08 (0.01,0.18) | 0.6 |
| PT(s)11.8 (10.9,12.7)11.85 (11.15,13)11.8 (10.9,12.78)0.446APTT(s)30 (27.8,32.88)30.05 (28.12,33.42)30 (27.9,33.32)0.502FIB(g/L)4.04 (3.1,5.01)4.44 (3.2,5.34)4.06 (3.11,5.04)0.254ALB(g/L)36.62 ± 6.1834.42 ± 5.736.15 ± 6.140.026GGT(U/L)25.5 (17,47)23 (15,38)24 (17,43)0.408ALT(U/L)29 (15,48)28 (21,49)29 (15.5,48.5)0.735AST(U/L)29.5 (19,57)36 (25,54)31 (19.5,57)0.175TBL(umol/L)12.3 (7.8,18.2)14.7 (9.5,21.7)12.55 (85,18.38)0.138Cr(umol/L)59 (47,72.25)53 (43.5,66)58 (46,71.5)0.209 | Baso(*10 ⁹ /L) | 0.02 (0.01.0.04) | 0.02 (0.01.0.03) | 0.02 (0.01.0.04) | 0.489 |
| APTT(s) 30 (27.8,32.88) 30.05 (28.12,33.42) 30 (27.9,33.32) 0.502 FIB(g/L) 4.04 (3.1,5.01) 4.44 (3.2,5.34) 4.06 (3.11,5.04) 0.254 ALB(g/L) 36.62 ± 6.18 34.42 ± 5.7 36.15 ± 6.14 0.026 GGT(U/L) 25.5 (17,47) 23 (15,38) 24 (17,43) 0.408 ALT(U/L) 29 (15,48) 28 (21,49) 29 (15.5,48.5) 0.735 AST(U/L) 29.5 (19,57) 36 (25,54) 31 (19.5,57) 0.175 TBL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (85,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 PUN(mmol(L) 40 (28.6,20) 48 (25.6,21) 4.90 (27.75.4) 0.474 | PT(s) | 11.8 (10.9.12.7) | 11.85 (11.15.13) | 11.8 (10.9.12.78) | 0.446 |
| FIB(g/L) 4.04 (3.1,5.01) 4.44 (3.2,5.34) 4.06 (3.11,5.04) 0.254 ALB(g/L) 36.62 ± 6.18 34.42 ± 5.7 36.15 ± 6.14 0.026 GGT(U/L) 25.5 (17,47) 23 (15,38) 24 (17,43) 0.408 ALT(U/L) 29 (15,48) 28 (21,49) 29 (15.5,48.5) 0.735 AST(U/L) 29.5 (19,57) 36 (25,54) 31 (19.5,57) 0.175 TBL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (8.5,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 PLIN(mmol(L)) 40 (28.6,20) 48 (25.6,51) 420 (27.7,6,4) 0.47.6 | APTT(s) | 30 (27.8.32.88) | 30.05 (28.12.33.42) | 30 (27.9.33.32) | 0.502 |
| ALB(g/L) 36.62±6.18 34.42±5.7 36.15±6.14 0.026 GGT(U/L) 25.5 (17,47) 23 (15,38) 24 (17,43) 0.408 ALT(U/L) 29 (15,48) 28 (21,49) 29 (15.5,48.5) 0.735 AST(U/L) 29.5 (19,57) 36 (25,54) 31 (19.5,57) 0.175 TBL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (8.5,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 PLIN(mmon(l)) 40 (2,86,620) 48 (2,55,621) 4.80 (2,77,64) 0.474 | FIB(q/L) | 4 04 (3 1 5 01) | 4 44 (3 2 5 34) | 4 06 (3 11 5 04) | 0 254 |
| GGT(U/L) 25.5 (17,47) 23 (15,38) 24 (17,43) 0.408 ALT(U/L) 29 (15,48) 28 (21,49) 29 (15.5,48.5) 0.735 AST(U/L) 29.5 (19,57) 36 (25,54) 31 (19.5,57) 0.175 TBIL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (8.5,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 | ALB(α/L) | 3662+618 | 34 42 + 5 7 | 3615+614 | 0.026 |
| ALT(U/L) 29 (15,48) 28 (21,49) 29 (15.5,48.5) 0.735 AST(U/L) 29.5 (19,57) 36 (25,54) 31 (19.5,57) 0.175 TBIL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (8.5,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 RUN(mmol/L) 4.9 (2.56,21) 4.80 (2.77,64) 0.4764 | GGT(U/L) | 25 5 (17 47) | 23 (15 38) | 24 (17 43) | 0.408 |
| AST(U/L) 29.5 (19,57) 36 (25,54) 31 (19.5,57) 0.175 TBIL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (8.5,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 RUN(mmol/L) 4.0 (3.86.620) 4.8 (3.55.631) 4.80 (3.77.641) 0.47.641 | AIT(U/I) | 29 (15 48) | 28 (21 49) | 29 (15 5 48 5) | 0.735 |
| TBIL(umol/L) 12.3 (7.8,18.2) 14.7 (9.5,21.7) 12.55 (8.5,18.38) 0.138 Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 RUN(mmol/L) 40 (2.3.96.20) 48 (2.5.6.21) 4.90 (2.7.7.6.4) 0.47.4 | AST(11/1) | 295 (1957) | 36 (25 54) | 31 (19 5 57) | 0.175 |
| Cr(umol/L) 59 (47,72.25) 53 (43.5,66) 58 (46,71.5) 0.209 RUN(mmol/L) 40 (2.866.20) 48 (2.55.6.31) 4.90 (2.77.6.4) 0.47.4 | TBIL (umol/L) | 123 (78182) | 147 (95 21 7) | 12 55 (8 5 18 38) | 0.175 |
| Cr(amor/c) 35 (43.3,00) 30 (40,71.3) 0.209 DI M/mmol/l) 4.0 (2.06.6.20) 4.9 (2.00 - 2.72.4.) 0.404 | | 59 (77 72 25) | 53 (43 5 66) | 58 (46 71 5) | 0.150 |
| 1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/1/ | | 1 Q (3 86 6 30) | л 8 (3 55 6 31) | A 80 (3 77 6 A) | 0.209 |

Table 2 Comparison of clinical factors between the DVT group and the No DVT group

Note: WBC: White blood cell count; RBC: Red blood cell count; HGB: Hemoglobin; MCV: Mean corpuscular volume; MCHC: Mean corpuscular hemoglobin concentration; NC: Neutrophils; LYM: Lymphocyte; MONO: Monocyte; Eos: Eosinophils; Baso: Basophil; ALB: Albumin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; TBIL: Total bilirubin; PT: Prothrombin time; APTT: Activated partial thrombin time; FIB: Fibrinogen; Cr: Creatinine; BUN: Blood urea nitrogen; MLR: Monocyte to lymphocyte ratio

a nomogram model was constructed using R studio software based on the results of the multivariate analysis (Age, WBC, MLR). The column line chart was constructed using the data from the training group, as shown in Fig. 4. The training group ROC curve was plotted to validate the predictive performance of the column line chart (Fig. 5A), with a C-index of 0.845, indicating good predictive performance. The training group calibration curve was plotted (Fig. 6A), which showed a mean error of 0.02. The training group decision curve analysis (DCA)



Fig. 2 Box plot of clinical differential factors

was plotted (Fig. 7A), indicating good clinical benefit within the threshold range of 0.01–0.99.

The validation group data was also used for validation. The ROC curve was plotted (Fig. 5B), with a C-index of

Table 3 The area under the ROC curve and its cutoff value for clinical factors with statistical differences

| Variable | AUC | AUC[95%CI] | p | Cutoff value | Sensitivity | specificity |
|---------------------------|-------|---------------|-------|--------------|-------------|-------------|
| RBC(*10 ¹² /L) | 0.635 | [0.557,0.713] | 0.002 | 3.505 | 0.621 | 0.652 |
| HGB(g/L) | 0.622 | [0.54,0.704] | 0.005 | 105.8 | 0.672 | 0.571 |
| MCV(fL) | 0.601 | [0.517,0.685] | 0.020 | 88.675 | 0.638 | 0.586 |
| WBC(*109/L) | 0.829 | [0.77,0.888] | 0.000 | 10.625 | 0.793 | 0.753 |
| NC(*10 ⁹ /L) | 0.836 | [0.777,0.895] | 0.000 | 8.515 | 0.793 | 0.758 |
| MLR | 0.696 | [0.616,0.776] | 0.000 | 0.506 | 0.759 | 0.591 |

Note: WBC: White blood cell count; RBC: Red blood cell count; HGB: Hemoglobin; MCV: Mean corpuscular volume; NC: Neutrophils; MLR: Monocyte to lymphocyte ratio



Fig. 3 Receiver operating characteristic of clinical differential factors

0.876. The calibration curve was plotted (Fig. 6B), showing a mean error of 0.032. The DCA was plotted (Fig. 7B), indicating good clinical benefit within the threshold range of 0.01–0.99.

It can be seen that the nomogram exhibited good predictive performance with small errors in both the training and validation groups, and it can benefit the majority of clinical patients.

Discussion

It is common for patients with fractures to develop deep vein thrombosis (DVT), and many scholars believe that DVT should be detected, prevented, and treated early [20–23]. Color Doppler ultrasound is considered the gold standard for diagnosing DVT and is often recommended to be performed early in the course of the disease [24]. However, in clinical practice, we have found that color Doppler ultrasound examinations can often result in significant errors due to difficulties in cooperation from patients with pelvic fractures and lower limb swelling,

| Variable | B | SE | Z | р | OR[95%CI] |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------|-------|---------|---------|-------------------|
| Sex | | | | • | |
| Male | | | | | 1 |
| Female | 0311 | 0.202 | 1.065 | 0.287 | 1 36[0 77 2 42] |
| | 0.511 | 0.272 | 1.005 | 0.207 | 1.50[0.77,2.42] |
| Age(years) | | | | | 1 |
| ≤ 50.5 | 0.505 | 0.004 | 4 9 9 4 | 0.0.17 | |
| > 50.5 | 0.585 | 0.294 | 1.991 | 0.047 | 1./9[1.01,3.19] |
| Hypertension | | | | | |
| No | | | | | 1 |
| Yes | 0.198 | 0.466 | 0.425 | 0.671 | 1.22[0.49,3.03] |
| Diabetes | | | | | |
| No | | | | | 1 |
| Yes | 0.229 | 0.603 | 0.379 | 0.705 | 1.26[0.39,4.1] |
| Heart disease | | | | | |
| No | | | | | 1 |
| Yes | 0.13 | 1 164 | 0112 | 0.911 | 1 14[0 12 11 15] |
| Smoke | 0.10 | | 0.112 | 0.511 | |
| No | | | | | 1 |
| No | 0 (2 1 | 0.200 | 1.(() | 0.007 | |
| res | -0.031 | 0.380 | -1.002 | 0.097 | 0.53[0.25,1.12] |
| Alcoholism | | | | | |
| No | | | | | 1 |
| Yes | -0.337 | 0.371 | -0.909 | 0.364 | 0.71[0.35,1.48] |
| Hepatitis | | | | | |
| No | | | | | 1 |
| Yes | -0.737 | 1.079 | -0.683 | 0.495 | 0.48[0.06,3.97] |
| RBC(*10 ¹² /L) | | | | | |
| ≤ 3.505 | | | | | 1 |
| > 3.505 | -1.118 | 0.309 | -3.619 | < 0.001 | 0.33[0.18,0.6] |
| HGB(a/L) | | | | | |
| < 105.8 | | | | | 1 |
| > 105.8 | -1 004 | 0314 | -3 192 | 0.001 | 0 37[0 2 0 68] |
| > 103.0 MC\/(fL) | 1.001 | 0.511 | 5.152 | 0.001 | 0.57 [0.2,0.00] |
| < 00.67E | | | | | 1 |
| ≤ 00.075 | 0.012 | 0.200 | 2.054 | 0.002 | |
| > 88.0/5 | 0.913 | 0.309 | 2.950 | 0.003 | 2.49[1.30,4.57] |
| MCHC(g/L) | | | | | |
| ≤ 329.05 | | | | | 1 |
| > 329.05 | -0.409 | 0.302 | -1.353 | 0.176 | 0.66[0.37,1.2] |
| WBC(*10 ⁹ /L) | | | | | |
| ≤10.625 | | | | | 1 |
| >10.625 | 2.456 | 0.364 | 6.755 | < 0.001 | 11.66[5.72,23.77] |
| NC(*10 ⁹ /L) | | | | | |
| ≤8.515 | | | | | 1 |
| >8.515 | 2.483 | 0.364 | 6.820 | < 0.001 | 11.98[5.87,24.45] |
| MLR | | | | | |
| ≤0.506 | | | | | 1 |
| >0.506 | 1513 | 0 339 | 4 460 | < 0.001 | 4 54[2 34 8 83] |
| 1 YM(*10 ⁹ /L) | 1.010 | 0.000 | 11100 | | 10 [210 [0100] |
| < 1.085 | | | | | 1 |
| ≤ 1.00J | 1 17 | 0.211 | 2761 | .0.001 | |
| < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2001 < 2 | -1.17 | 0.311 | -3./01 | < 0.001 | 0.31[0.17,0.57] |
| MONO(*101/L) | | | | | |
| ≤0.6/5 | | | | | 1 |
| > 0.675 | 1.181 | 0.308 | 3.833 | < 0.001 | 3.26[1.78,5.96] |
| Eos(*10 ⁹ /L) | | | | | |
| ≤ 0.095 | | | | | 1 |

 Table 4
 Single factor binary logistic regression analysis results

| Variable | В | SE | Z | р | OR[95%CI] |
|---------------------------|--------|-------|--------|-------|------------------|
| > 0.095 | -0.278 | 0.301 | -0.923 | 0.356 | 0.76[0.42,1.37] |
| Baso(*10 ⁹ /L) | | | | | |
| ≤0.105 | | | | | 1 |
| > 0.105 | 0.542 | 1.234 | 0.439 | 0.661 | 1.72[0.15,19.31] |
| PT(s) | | | | | |
| ≤10.75 | | | | | 1 |
| > 10.75 | 0.71 | 0.511 | 1.391 | 0.164 | 2.03[0.75,5.53] |
| APTT(s) | | | | | |
| ≤26.45 | | | | | 1 |
| > 26.45 | 1.35 | 0.753 | 1.792 | 0.073 | 3.86[0.88,16.89] |
| FIB(g/L) | | | | | |
| ≤4.8 | | | | | 1 |
| >4.8 | 0.67 | 0.345 | 1.943 | 0.052 | 1.96[0.99,3.85] |
| ALB(g/L) | | | | | |
| ≤36.15 | | | | | 1 |
| > 36.15 | -0.881 | 0.336 | -2.622 | 0.009 | 0.41[0.21,0.8] |
| GGT(U/L) | | | | | |
| ≤12.5 | | | | | 1 |
| >12.5 | -0.882 | 0.457 | -1.929 | 0.054 | 0.41[0.17,1.01] |
| ALT(U/L) | | | | | |
| ≤60.5 | | | | | 1 |
| >60.5 | -0.767 | 0.508 | -1.510 | 0.131 | 0.46[0.17,1.26] |
| AST(U/L) | | | | | |
| ≤23.5 | | | | | 1 |
| >23.5 | 0.865 | 0.401 | 2.157 | 0.031 | 2.38[1.08,5.21] |
| TBIL(umol/L) | | | | | |
| ≤13.75 | | | | | 1 |
| >13.75 | 0.595 | 0.326 | 1.824 | 0.068 | 1.81[0.96,3.44] |
| Cr(umol/L) | | | | | |
| ≤54.5 | | | | | 1 |
| >54.5 | -0.701 | 0.333 | -2.108 | 0.035 | 0.5[0.26,0.95] |
| BUN(mmol/L) | | | | | |
| ≤ 3.83 | | | | | 1 |
| > 3.83 | -0.626 | 0.353 | -1.772 | 0.076 | 0.53[0.27,1.07] |

Annotation: SE: Standard Error; OR: Odds Ratios; 95%CI: 95% Confidence Interval

among other factors. Therefore, there is an urgent need for more simple methods to further predict the occurrence of DVT in order to benefit more patients.

The occurrence of deep vein thrombosis may be related to venous stasis caused by immobilisation after fracture, hypercoagulable states in trauma patients, endothelial injury, and an inflammatory response [25]. Blood coagulation is a finely regulated process, and when inflammation is dysregulated or spontaneous in certain diseases, it

 Table 5
 Multivariate binary logistic regression analysis results

| Variable | В | SE | z | р | OR[95%CI] |
|----------------------------------------------------------------------------------|-------|-------|-------|---------|-----------------|
| Age | 0.039 | 0.014 | 2.727 | 0.006 | 1.04[1.01,1.07] |
| (years) | | | | | |
| WBC(*10 ⁹ /L) | 0.364 | 0.059 | 6.218 | < 0.001 | 1.44[1.28,1.61] |
| MLR | 0.747 | 0.342 | 2.182 | 0.029 | 2.11[1.08,4.13] |
| Apportation: SE: Standard Error: OP: Odds Patios: 95% Cl: 95% Confidence Interva | | | | | |

otation: SE: Standard Error; OR: Odds Ratios; 95%CI: 95% Confidence Interval

can promote thrombotic diseases [26]. Chemotactic factors can induce thrombus formation by forming immune complexes with heparin or other polyanions that activate platelets. In addition, chemotactic factors can alter the charge on the surface of platelets and interact with coagulation factors to regulate the balance between fibrinolysis and coagulation [27]. Some reports have suggested that inflammasome pathway activation occurs in patients with venous thromboembolism, and the main mechanism may involve involvement in inflammatory reactions and oxidative stress, promoting the formation of deep vein thrombosis. Inhibition of inflammasome signalling can reduce venous thrombus formation and vascular damage [28, 29]. Han Jinan et al. [30] experimentally verified that decreased expression of miR-128-3p is beneficial for cell proliferation and migration and inhibits inflammation, apoptosis, and adhesion of human umbilical vein



Fig. 4 The nomogram of the study

endothelial cells, thereby reducing the risk of deep vein thrombosis. In addition, NF- κ B, as a transcription factor, is one of the central mediators of inflammation, and the NF- κ B signalling pathway can regulate pro-inflammatory and pro-coagulation reactions, leading to venous thromboembolism [31]. The formation of neutrophil extracellular traps, accompanied by the release of extracellular decondensed chromatin and pro-inflammatory and prothrombotic factors, is a key factor in the development and progression of thrombotic occlusive diseases [32].

In recent years, more and more literature has focused on the predictive factors of deep vein thrombosis after lower limb fractures. Hongyu Meng et al. [33] conducted a prospective study to verify the predictors of preoperative DVT in isolated calcaneal fractures and proposed that for elderly patients with delayed hospital admission and elevated plasma D-dimer levels, targeted detection of DVT and rapid therapeutic intervention should be emphasized. Kuo Zhao et al. [34] suggested that although anticoagulant therapy is routinely used to prevent DVT formation, the incidence of DVT is still high, and it is recommended to perform ultrasound examination of both lower limbs before surgery, especially for patients with delayed surgery, hypoproteinemia, and 3 or more comorbidities. Although some scholars have proposed predictive factors for DVT in patients with pelvic fractures, no predictive model based on inflammatory indicators has been proposed [35, 36]. At the same time, some scholars have emphasised the great advantages of inflammatory indicators: low cost, quick availability, and early



Fig. 5 Receiver operating characteristic of nomogram. A. Training test; B. Validation test



Fig. 6 Calibration plot of the nomogram. A. Training test; B. Validation test



Fig. 7 DCA curve of the nomogram. A. Training test; B. Validation test

identification of high-risk patients with adverse events [37]. In this study, a nomogram was constructed based on MLR, and the results showed that the model had good predictive performance, small average error, and good clinical benefits. It can help clinicians make relevant predictions and judgments when patients are admitted, and take preventive measures.

This study has several advantages: (1) This study is the first to use inflammatory factors as predictive indicators to construct a column chart, which reflects the characteristics of convenience, speed, and ease of use. (2) This study aims to collect relevant serological examination data at the time of patient admission to achieve early prediction and benefit more patients. (3) The models constructed in the training and validation groups in this study have good predictive performance, small average error, and significant clinical benefits. However, this study also has the following limitations: (1) as a single center study, only internal validation is conducted, and further external validation is required using data from multiple centers; (2) The sample size of this study can be further expanded; (3) We can also explore the mechanism by which inflammatory markers affect the occurrence of deep vein thrombosis through further in vivo and in vitro experiments; (4) This study did not explore the occurrence of postoperative deep vein thrombosis in patients with pelvic fractures.

Conclusion

The Age, WBC, and MLR at the time of admission in patients with pelvic fractures are independent predictive factors for DVT. The nomogram constructed based on MLR can help clinicians assess the probability of DVT occurrence early, achieve early prevention and treatment, and benefit more patients.

Abbreviations

| DVT WBC RBC HGB MCV MCHC NC LYM MONO Eos Baso ALB AST ALT TBIL PT APTT | Deep venous thrombosis White blood cell count Red blood cell count Hemoglobin Mean corpuscular volume Mean corpuscular hemoglobin concentration Neutrophils Lymphocyte Eosinophils Basophil Albumin Aspartate aminotransferase Alanine aminotransferase Total bilirubin Prothrombin time Activated partial thrombin time |
|------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| APTT FIB Cr | Activated partial thrombin time Fibrinogen Creatinine |
| | |

- BUN Blood urea nitrogen MIR Monocyte to lymphocyte ratio OR Odds ratio CI Confidence interval
- AUC
- The area under the curve DCA Decision curve analysis
- ROC Receiver operating characteristic

Acknowledgements

Not applicable.

Author contributions

RBL designed this study. WCL and HL are responsible for writing articles, conducting statistical analysis, reviewing articles, and creating images. ZH, YHL, JJL, WS and GYD are responsible for collecting data and conducting statistical analysis. All authors reviewed the manuscript. All authors read and approved the final manuscript.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Data availability

The data used to support the findings of this study are available from the corresponding author upon request.

Declarations

Ethics approval and consent to participate

This study was conducted in accordance with the Declaration of Helsinki (as revised in 2013) and was approved by the First Affiliated Hospital of Guangxi Medical University Ethics Review Committee (2023-E584-01). Exemption of informed consent from patients with the consent of the ethics committee.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Received: 27 December 2023 / Accepted: 14 October 2024 Published online: 25 October 2024

References

- Khalifa AA, Mahran DG, Fergany A, Farouk O. Epidemiology of acetabular fractures in elderly patients and the effect of various management options on the outcomes. A comprehensive narrative review. Int J Orthop Trauma Nurs. 2024;101049. https://doi.org/10.1016/j.ijotn.2023.101049
- Moore D, Gnap R, Monsell F. Traumatic injuries of the immature hip 2. and pelvis. Curr OpinPediatr. 2024;36(1):90-7. https://doi.org/10.1097/ MOP00000000001301
- Warner Stephen J, Haase Douglas R, Chip Routt Milton L, Eastman Jonathan 3. G, Achor Timothy S. Use of 3D fluoroscopy to assist in the reduction and fixation of pelvic and Acetabular fractures: a Safety and Quality Case Series. J Orthop Trauma. 2023;37(null):S1-6. https://doi.org/10.1097/ BOT.00000000002686
- Wier Julian, Reza F, Andrew D, Patterson Joseph T. Underweight patients experience higher inpatient complication and mortality rates following acetabular fracture. Eur J Orthop Surg Traumatol. 2023. https://doi.org/10.1007/ s00590-023-03739-z
- Hsiao P-M, Chen LS-C, Yu Yi-Hsun. Incidence of deep vein thrombosis and 5. symptomatic pulmonary embolism in Taiwanese patients with pelvic and/or acetabular fractures: a retrospective study. Sci Rep. 2023;13(1):16352. https:// doi.org/10.1038/s41598-023-43449-4.
- 6. Kwon H, Jang JH, Moon NH, Rhee SJ, Ryu DY, Ahn TY. Superior gluteal artery injury in pelvic ring injury and acetabular fracture: Single center observational study. J Orthop Sci. 2023. https://doi.org/10.1016/j.jos.2023.10.007

- 7. Freigang V, Nike W, Markus R. R. M, Alt V, Baumann F.(2023). Treatment of Fracture-Related Infection after Pelvic Fracture. J Clin Med, 12(19). https://doi. org/10.3390/jcm12196221
- George J, Sharma V, Farooque K, Mittal S, Trikha V, Malhotra R. The Impact of Surgical Timing of Hip Fracture on Mortality: Do the Cause and Duration of Delay Matter? Hip Pelvis. 2023;35(3):206-15. https://doi.org/10.5371/ hp 2023 35 3 206
- 9 Mennen AH, Oud S, Halm JA, Peters RW, Willems HC, Van Embden D. Pelvic Ring fractures in older adult patients-assessing physician practice variation among (Orthopedic) Trauma surgeons. J Clin Med. 2023;12(19). https://doi. org/10.3390/jcm12196344.
- 10. Wu Q, Wu J, Tian S, Gao W, Li Z, Bai X, Liu T. Pulmonary embolism following severe polytrauma: a retrospective study from a level I trauma center in China. Eur J Trauma Emerg Surg. 2023;49(4):1959-67. https://doi.org/10.1007/ s00068-023-02290-0
- Shi D, Bao B, Zheng X, Wei H, Zhu T, Zhang Y, Zhao G. Risk factors for deep 11. vein thrombosis in patients with pelvic or lower-extremity fractures in the emergency intensive care unit. Front Surg, 2023;10:1115920. https://doi. org/10.3389/fsurg.2023.1115920
- 12. Hadizie D, Deyoi YB, Faisham WI, Yahaya S, Ghani SA, Ahmad-Mohd-Zain MR. Study of deep vein thrombosis screening by using Ultrasound Doppler in patients with pelvic and Acetabulum fractures requiring operative intervention. Malays Orthop J. 2022;16(1):51-7. https://doi.org/10.5704/MOJ.2203.008.
- 13. Xue J, Ma D, Jiang J, Liu Y. Diagnostic and Prognostic Value of Immune/ Inflammation biomarkers for venous thromboembolism: is it Reliable for Clinical Practice? J Inflamm Res. 2021;14:5059-77. https://doi.org/10.2147/JIR. \$327014
- 14. Melinte RM, Arbănași EM, Blesneac A, Zolog DN, Kaller R, Mureșan AV, Arbănași E M, Melinte IM, Niculescu R, Russu E. Inflammatory Biomarkers as Prognostic Factors of Acute Deep Vein Thrombosis Following the Total Knee Arthroplasty. Medicina (Kaunas), 2022;58(10). https://doi.org/10.3390/ medicina58101502
- 15. Zhang L, He M, Jia W, Xie W, Song Y, Wang H, Peng J, Li Y, Wang Z, Lin Z. Analysis of high-risk factors for preoperative DVT in elderly patients with simple hip fractures and construction of a nomogram prediction model. BMC Musculoskelet Disord, 2022;23(1):441. https://doi.org/10.1186/s12891-022-05377-8
- Gao Z, Zhao K, Jin L, Lian X, Zhang Z, Ma L, Hou Z. Combination of neutrophil 16 to lymphocyte ratio, platelet to lymphocyte ratio with plasma D-dimer level to improve the diagnosis of deep venous thrombosis (DVT) following ankle fracture. J Orthop Surg Res, 2023;18(1):362. https://doi.org/10.1186/ s13018-023-03840-3
- 17. Melinte RM, Arbănași EM, Blesneac A, Zolog DN, Kaller R, Mureșan AV, Arbănași EM, Melinte IM, Niculescu R, Russu E. Inflammatory biomarkers as prognostic factors of acute deep vein thrombosis following the total knee arthroplasty [J]. Medicina (Kaunas). 2022;58(10):1502.
- Paul N, Cynthia B, Draga J et al. Prophylaxis of Venous Thrombosis in Neurocritical Care Patients: An Evidence-Based Guideline: A Statement for Healthcare Professionals from the Neurocritical Care Society J Neurocrit Care. 2015;24.
- 19. Rebecca G, Theophanous, Vinca W, Chow, David L, Convissar, et al. Point-Of-Care Ultrasound Screening for proximal lower extremity deep venous Thrombosis.[J] J Vis Exp. 2023;0:0.
- 20. Marigi EM, Sperling Jr JW, De Marinis R, Gupta P, Hassett LC, Soza F, Sanchez-Sotelo J. Venous thromboembolism following surgical management of proximal humerus fractures: a systematic review. JSES Rev Rep Tech. 2023;3(4):494-8. https://doi.org/10.1016/j.xrrt.2023.06.003
- 21. Jones A, Al-Horani RA. Venous thromboembolism Prophylaxis in Major Orthopedic surgeries and factor XIa inhibitors. Med Sci (Basel). 2023;11(3). https:// doi.org/10.3390/medsci11030049.
- 22. Núñez JH, Moreira F, Escudero-Cisneros B, Martínez-Peña J, Bosch-García D, Angles F, Guerra-Farfán E. Risk of venous thromboembolism in thromboprophylaxis between aspirin and low molecular weight heparins after total hip arthroplasty or total knee arthroplasty: Systematic review and meta-analysis. Rev Esp Cir Ortop Traumatol. 2023. https://doi.org/10.1016/j. recot 2023 07 003
- Encke A, Haas S, Kopp I. The Prophylaxis of Venous Thromboembolism. Dtsch Arztebl Int. 2016;113:532-8. https://doi.org/10.3238/arztebl.2016.0532
- 24. Akram F, Fan BE, Tan CW, Teoh WC, Prandoni P, Yap ES. The clinical application of venous ultrasound in diagnosis and follow-up of lower extremity deep vein thrombosis (DVT): a case-based discussion. Thromb J. 2023;21(1):110. https://doi.org/10.1186/s12959-023-00550-y

- Whiting PS, Jahangir AA. Thromboembolic disease after orthopedic trauma. Orthop Clin North Am. 2016;47:335–44.
- Watson C, Saaid H, Vedula V, Cardenas JC, Henke PK, Nicoud F, Xu XY, Hunt BJ, Manning KB. Venous Thromboembolism: Review of Clinical Challenges, Biology, Assessment, Treatment, and Modeling. Ann Biomed Eng. 2023. https:// doi.org/10.1007/s10439-023-03390-z
- Leberzammer J, von Hundelshausen P. Chemokines, molecular drivers of thromboinflammation and immunothrombosis. Front Immunol. 2023;14:1276353. https://doi.org/10.3389/fimmu.2023.1276353.
- Potere N, Abbate A, Kanthi Y, Carrier M, Toldo S, Porreca E, Di Nisio M. Inflammasome Signaling, Thromboinflammation, and Venous Thromboembolism. JACC Basic Transl Sci. 2023;8(9):1245–61. https://doi.org/10.1016/j. jacbts.2023.03.017
- Fei J, Wang H, Han J, Zhang X, Ma H, Qin X, Yu C, Jiang J. TXNIP activates NLRP3/IL-1β and participate in inflammatory response and oxidative stress to promote deep venous thrombosis. Experimental Biology and Medicine. 2023 Sep;248(18):1588-97. https://doi.org/10.1177/15353702231191124
- Han J, Hao W, Ma Y, Hou Y. MiR-128-3p promotes the progression of deep venous thrombosis through binding SIRT1. Phlebology. 2023;38(8):540–9. https://doi.org/10.1177/02683555231190268
- Wang Z, Chucun F, Mengting Y, Maga W, Mo Jianwen. Guo Tianting., Research progress of NF-kB signaling pathway and thrombosis. Front Immunol, 2023;14:1257988. https://doi.org/10.3389/fimmu.2023.1257988
- Zdanyte M, Borst O, Münzer P. NET-(works) in arterial and venous thromboocclusive diseases. Front Cardiovasc Med. 2023;10:1155512. https://doi. org/10.3389/fcvm.2023.1155512

- Meng H, Zhu Y, Zhang J, et al. Incidence and risk factor for preoperative deep vein thrombosis (DVT) in isolated calcaneal fracture, a prospective cohort study. Foot Ankle Surg. 2021;27(5):510–4. https://doi.org/10.1016/j. fas.2020.06.007.
- Zhao K, Wang Z, Tian S, Hou Z, Chen W, Zhang Y. Incidence of and risk factors for pre-operative deep venous thrombosis in geriatric intertrochanteric fracture patients [published correction appears in. Int Orthop. 2022;46(4):929. https://doi.org/10.1007/s00264-021-05297-7.
- 35. Yang Zongyou, Ren R, Zhizhou Y, Hucheng Y, Yingchao Y, Zhiyong T. Development and validation of a nomogram for predicting deep venous thrombosis in patients with pelvic and acetabular fractures: a retrospective cohort study: Predictive model for pelvic/acetabular fractures. BMC Musculoskelet Disord. 2023;24(1):773. https://doi.org/10.1186/s12891-023-06879-9
- Zhang H, Wu L, Cheng B. Preoperative anemia and deep vein thrombosis in patients with perioperative bone trauma: a cohort study. BMC Musculoskelet Disord. 2022;23(1):905. https://doi.org/10.1186/s12891-022-05869-7.
- Serra R, Ielapi N, Licastro N, Provenzano M, Andreucci M, Bracale UM, Jiritano F, de Franciscis S, Mastroroberto P, Serraino GF. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio as biomarkers for Cardiovascular surgery procedures: a literature. Rev [J] Rev Recent Clin Trials. 2021;16:173–9.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.